By identifying the EGFR 15/18 bp deletions in blood, the ultra high analytical selectivity of MAP could potentially be applied to early lung cancer detection or possibly facilitate more rational chemotherapy delivery by monitoring the efficacy of therapy or predicting recurrence. This evidence concerns the gene EGFR and lung cancer.